|
|
|
| Clinical Effect of TP Chemotherapy Combined with Xihuang Pills and Press Needle Therapy on Advanced Ovarian Cancer |
| XU Yan |
| Ganzhou Cancer Hospital, Jiangxi Province, Ganzhou 341000, China |
|
|
|
|
Abstract Objective: To investigate the effect of TP chemotherapy combined with Xihuang Pills and press needle therapy in advanced ovarian cancer. Method: A total of 70 patients with advanced ovarian cancer admitted to Ganzhou Cancer Hospital from January 2020 to June 2022 were selected, they were randomly divided into two groups, 35 patients in each group. Both groups were treated with tumor cytoreductive surgery, the control group was treated with TP chemotherapy after surgery, and the observation group was treated with Xihuang Pills and press needle on the basis of the control group, treatment continued for 12 weeks. The clinical efficacy, tumor marker level, immune function, immunoglobulin level, quality of life and adverse reactions were compared between the two groups. Result: The total effective rate in the observation group was higher than that in the control group, the difference was statistically significant (P<0.05). The levels of carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199) and carbohydrate antigen 153 (CA153) in the observation group were lower than those in the control group, the levels of CD3+, CD4+, CD4+/CD8+ were higher than those in the control group, and CD8+ was lower than that in the control group, the levels of IgG, IgA and IgM were higher than those in the control group, the physiological, psychological, social and environmental scores were higher than those in the control group, and the incidence of bone marrow suppression and gastrointestinal reactions were lower than those in the control group, the differences were statistically significant (P<0.05). Conclusion: TP chemotherapy combined with Xihuang Pills and press needle can improve the curative effect of patients with advanced ovarian cancer, accelerate the normalization of tumor markers, protect immune function, reduce adverse reactions of chemotherapy, and improve the quality of life.
|
|
Received: 06 January 2023
|
|
|
|
|
|
|
